Melphalan

Melphalan works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This DNA damage leads to cell‑cycle arrest and triggers programmed cell death, particularly in rapidly dividing cancer cells.

The dose of melphalan is individualized and determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function, and treatment protocol. No fixed regimen is provided here; dosing must follow a qualified healthcare professional’s order.

Melphalan is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated during pregnancy and should not be used by breastfeeding mothers because it can be excreted in milk and may harm the infant.

To order melphalan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Melphalan belongs to the nitrogen‑mustard alkylating class, similar to cyclophosphamide and ifosfamide. Compared with cyclophosphamide, melphalan often shows higher potency in certain hematologic malignancies but may have a greater risk of myelosuppression and secondary cancers. Choice of agent depends on disease indication, patient tolerance, and physician preference.

Melphalan should be stored at controlled room temperature, protected from light and moisture, and kept in its original packaging. The solution must be handled by trained personnel using aseptic technique, and any unused portion should be discarded according to local hazardous‑drug regulations.

Melphalan is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. Infusion rates and duration are determined by the prescribing protocol and patient tolerance.

The most serious risks include severe neutropenia leading to infection, secondary malignancies such as therapy‑related leukemia, pulmonary toxicity (interstitial pneumonitis or fibrosis), and profound bone‑marrow suppression causing anemia or thrombocytopenia. Patients should be monitored closely for signs of infection, respiratory distress, or abnormal blood counts.

Melphalan is contraindicated in patients with known hypersensitivity to the drug, pregnant or nursing women, those with active severe infections, and individuals with severe bone‑marrow failure. Caution is also advised for patients with significant renal or hepatic impairment, as dose adjustments may be required.